Ligand Pharmaceuticals Incorporated (LGND) Q3 2012 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Up 6.43%

Ligand Pharmaceuticals reported a smaller-than-expected loss per share, which led to a positive stock reaction, rising 6.43%. The earnings surprise indicates better-than-anticipated cost management or operational efficiency. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.01	N/A	+85.71%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management seemed pleased with the earnings surprise on EPS. However, they did not provide detailed insights into revenue or future guidance.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They highlighted ongoing projects and potential future developments.

Ligand Pharmaceuticals Beats on EPS, Stock Up 6.43%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Up 6.43%

Key numbers

Management commentary